Zhitong Financial App News, Hehuang Pharmaceutical (00013.HK) today announced the positive summary results of the SAVANNAH Phase II study. The combination therapy with TAGRISSO® (TAGRISSO®, osimertinib) and ORPATHYS® (ORPATHYS®, savolitinib) progressed after previous treatment with Teresa®, and was accompanied by high levels of mesenchymal epithelial converting factor overexpression and/or amplification (defined as IHC90+ and/or FISH10+) Non-small cell lung cancer patients with growth factor receptor mutations showed a high, clinically significant, and long-lasting improvement in objective remission rates. The above data will be presented at an upcoming academic conference and shared with global regulators.

Zhitongcaijing · 10/16 04:33
Zhitong Financial App News, Hehuang Pharmaceutical (00013.HK) today announced the positive summary results of the SAVANNAH Phase II study. The combination therapy with TAGRISSO® (TAGRISSO®, osimertinib) and ORPATHYS® (ORPATHYS®, savolitinib) progressed after previous treatment with Teresa®, and was accompanied by high levels of mesenchymal epithelial converting factor overexpression and/or amplification (defined as IHC90+ and/or FISH10+) Non-small cell lung cancer patients with growth factor receptor mutations showed a high, clinically significant, and long-lasting improvement in objective remission rates. The above data will be presented at an upcoming academic conference and shared with global regulators.